MLMengya Liang

Mengya Liang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mengya Liang has a total of 80 co-authors. Here are the top co-authors by number of shared publications:

  • Zhongkai Wu

    Department of Cardiac Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

    21 shared publications
  • Suiqing Huang

    Department of Cardiac Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

    11 shared publications
  • Bohao Jian

    Department of Cardiac Surgery, The First Affiliated Hospital of Sun Yat-Sen University

    9 shared publications
  • Guangguo Fu

    Department of Cardiac Surgery, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China

    9 shared publications
  • Zhuoming Zhou

    Department of Cardiac Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

    9 shared publications
  • Jiantao Chen

    Department of Cardiac Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

    8 shared publications

Latest Publications

  • Open Access

    Cumulative exposure of the combined triglyceride-glucose and frailty index for incident hypertension prediction in middle-aged and older adults: a national cohort study

    by Yi Zhang, Huayang Li, Jiachen Niu, Quan Liu, Hanri Xiao, Hanlin Chen, Zhuoming Zhou, Mengya Liang, Zhongkai Wu

  • Open Access

    Fluorofenidone ameliorates pressure overload-induced heart failure by stabilizing SERCA2a in male mice

    by Quan Liu, Huayang Li, Jiantao Chen, Qiushi Ren, Tongxin Chu, Li Luo, Zeyu Li, Suiqing Huang, Liqun Shang, Adilai Maihemuti, et al.

  • Open Access

    Four and a half Lin11, Isl-1, Mec-3(LIM) domain protein 1 (FHL1) regulates vascular remodeling in low-flow vein grafts

    by Chaoqun Wang, Jiantao Chen, Guangxian Chen, Jianbo Liao, Suiqing Huang, Kangni Feng, Ziyin Ye, Mengya Liang, Zhongkai Wu

    Background: Neointimal hyperplasia (NIH) is a critical determinant of long-term patency of vein grafts following coronary artery bypass grafting (CABG). The development of neointima is influenced by hemodynamic conditions. Our previous studies have demonstrated that four and a half LIM domain protein 1 (FHL1) effectively attenuates neointimal formation in vein grafts under normal flow conditions. However, the role of FHL1 in low-flow hemodynamic environments remains unclear. Elucidating the mechanisms underlying NIH in low-flow settings is essential for improving low-flow vein graft outcomes. Methods: The vein graft model was established in Sprague-Dawley (SD) rats, with low blood flow induced by ligation of the internal carotid artery. Then eointimal area was quantified using histological staining, while the expression of neointimal markers was assessed via immunofluorescence analysis. FHL1-knockout SD rats and SD rats with adenovirus-mediated FHL1 overexpression were used to evaluate the progression of NIH under low-flow conditions. Results: Following internal carotid artery ligation, the mean blood flow velocity in the vein grafts decreased immediately ( p < 0.0001), resulting in a significant increase in the neointimal area at 28 days post-surgery ( p < 0.05). In FHL1-knockout rats under low-flow conditions, NIH was further exacerbated ( p < 0.001), accompanied by marked downregulation of mature smooth muscle cell markers ( p < 0.05) and decreased proliferative activity ( p < 0.0001), reduced inflammatory mediators ( p < 0.0001), and activation of the mitogen-activated protein kinase (MAPK) signaling pathway ( p < 0.01). Conversely, FHL1 overexpression in low-flow grafts led to a reduction in neointimal thickening ( p < 0.05), promoted phenotypic maturation of neointimal cells ( p < 0.05), and suppressed proliferative activity ( p < 0.05), MAPK pathway activation ( p < 0.01), and inflammatory responses ( p < 0.01). Conclusion: In low-flow vein grafts, FHL1 may promote favorable vascular remodeling by inhibiting the MAPK signaling pathway, thereby attenuating neointimal cell phenotype switching and mitigating vascular inflammation.

  • Open Access

    Clinical efficacy and safety of transcatheter aortic valve replacement for patients with severe pure native aortic regurgitation

    by Jiantao Chen, Yi Zhang, Kangni Feng, Suiqing Huang, Hanri Xiao, Mengya Liang, Zhongkai Wu

    Objective To evaluate the early clinical efficacy and safety of trans-catheter aortic valve replacement (TAVR) for patients with severe pure native aortic regurgitation (PNAR). Methods A retrospective analysis was conducted on 48 PNAR patients who underwent TAVR at the Department of Cardiac Surgery, the First Affiliated Hospital of Sun Yat-sen University between March 2019 and February 2025, including 25 cases with transfemoral approach (TF-TAVR group) and 23 cases with transapical approach (TA-TAVR group). Efficacy and safety were assessed by analyzing baseline characteristics, all-cause mortality, and procedure-related complications. Results Compared with the TA-TAVR group, the TF-TAVR group exhibited significantly smaller aortic annulus circumference and diameter, left ventricular outflow tract circumference and diameter, diameters of the left, right, and non-coronary sinuses, and sinotubular junction (STJ) diameter, with a shorter distance from the STJ to the aortic valve basal ring plane (all P0.05). No conduction block events occurred in TA-TAVR group, while high-grade atrioventricular block, left bundle branch block, permanent pacemaker implantation occurred in TF-TAVR group during hospitalization or 1-year follow-up (12.00%, 4.00%, and 12.00%, respectively). Conclusions TAVR demonstrates high success rates and acceptable safety for severe PNAR patients who are unable to undergo traditional surgical procedures. Although TF-TAVR may face more challenges in certain complex cases than TA-TAVR, the overall outcomes are promising.


  • Open Access

    Identification of clinical phenotypes and heterogeneous treatment effects of surgical revascularization in ischaemic cardiomyopathy: a machine learning consensus clustering analysis

    by Tongxin Chu, Zhuoming Zhou, Huayang Li, Han Hu, Pengning Fan, Suiqing Huang, Jiatang Xu, Qiushi Ren, Qingyang Song, Gang Li, et al.

    Aims: To identify ischaemic cardiomyopathy (ICM) patients with different phenotypes for evaluating their outcomes and heterogeneous treatment effects (HTEs) of coronary artery bypass grafting (CABG). Methods and results: We applied a machine learning-based consensus, K-Medoids clustering analysis to the Surgical Treatment for Ischemic Heart Failure trial. We compared the risk of all-cause mortality and cardiovascular mortality among different phenotypes. The survival benefits of CABG compared with medical therapy alone were assessed in the identified phenotypes for evaluating HTEs. The consensus clustering analysis identified three distinct clinical phenotypes among 1212 ICM patients based on 19 variables. Specifically, phenotype 1 (n = 371) was characterized by younger ages, higher left ventricular ejection fraction (LVEF), and lower left ventricular end-systolic volume index (n = 371). Phenotype 2 had higher angina grades and more left main/left anterior descending artery stenosis (n = 520). Phenotype 3 had lower LVEF, higher New York Heart Association (NYHA) grades, more diabetes, and less hypertension (n = 321). After a median of 9.8 follow-up years, phenotype 3 had the highest risk of all-cause mortality [hazard ratio (HR), 1.96; 95% confidence intervals (CI), 1.62–2.37] and cardiovascular mortality (HR, 2.46; 95% CI, 1.95–3.10) compared to phenotype 1. Among phenotype 3, CABG provided significant survival benefits in all-cause mortality (HR, 0.75; 95% CI, 0.58–0.96) and cardiovascular mortality (HR, 0.67; 95% CI, 0.50–0.90) compared with medical therapy alone. Conclusion: We identified three phenotypes with distinct outcomes and HTEs among ICM patients. Patients with lower LVEF, higher NYHA grades, and diabetes had the poorest clinical outcomes but were more likely to derive greater survival benefits from CABG.


  • Coronary Artery Bypass Grafting With or Without Concomitant Surgical Ventricular Reconstruction in Ischemic Cardiomyopathy Patients

    by Jianbo Liao, Zhuoming Zhou, Yi Zhang, Zhilin Miao, Gang Li, Hanri Xiao, Qiushi Ren, Bohao Jian, Zhongkai Wu, Mengya Liang

    Purpose The present study aims to compare the long-term outcomes of surgical ventricular reconstruction (SVR) combined with coronary artery bypass grafting (CABG) versus CABG alone in patients with ischemic cardiomyopathy (ICM). Methods A systematic literature search was conducted in PubMed, Embase, Scopus, Cochrane Library, and Web of Science until November 2024. Studies comparing SVR + CABG and CABG in patients with ischemic cardiomyopathy (left ventricular ejection fraction less than 40%) were included. The primary outcome included long-term mortality, and the secondary outcomes included hospital mortality, rehospitalization for cardiac causes, and other cardiac function indicators. Results Twelve studies with a total of 3188 patients were included, with 1629 undergoing SVR + CABG and 1559 undergoing CABG. Patients who underwent SVR + CABG had a higher survival rate (HR 0.82; 95% CI, 0.69–0.96; I2 = 4%; P = 0.01) and a more significant postoperative left ventricular end-systolic volume index (ESVI) reduction (MD 15.53; 95% CI, 6.41–24.65; I2 = 93%; P = 0.01). In the subgroup analysis, the Dor (endoventricular circular patch plasty) surgery provided additional survival benefits compared with CABG (HR 0.83; 95% CI, 0.70–0.97; I2 = 9%; P = 0.02). The reconstructed Kaplan–Meier curves show that the survival rates in the SVR + CABG, Dor, Non-Dor, Mannequin-free, Mannequin, and CABG groups were 81.13%, 82.02%, 76.38%, 83.23%, 69.40%, and 71.42% at 60 months, respectively. Conclusions Compared with CABG, SVR + CABG is associated with higher survival, a more significant reduction in ESVI, fewer rehospitalizations for cardiac causes, and more patients gaining postoperative New York Heart Association class improvement. Graphical Abstract We collected data from patients who underwent either SVR+CABG or CABG surgery, and created forest plots and survival curves. Our analysis revealed that SVR+CABG results in better survival rates compared to CABG alone. These findings suggest that adding SVR surgery can provide clinical benefits for patients with ischemic cardiomyopathy, and it can be factored into the designs of future investigations in ischemic cardiomyopathy. Reconstructed survival curves of CABG and SVR+CABG.


  • Open Access

    The triglyceride-glucose index and acute kidney injury risk in critically ill patients with coronary artery disease

    by Yi Zhang, Gang Li, Junjie Li, Bohao Jian, Keke Wang, Jiantao Chen, Jian Hou, Jianbo Liao, Zhuoming Zhou, Zhongkai Wu, et al.

    The triglyceride-glucose (TyG) index, proven a reliable and simple surrogate of insulin resistance, has shown potential associations with cardiovascular outcomes and renal diseases. This research delved into the utility of the TyG index in predicting the risk of acute kidney injury (AKI) in patients with coronary artery disease (CAD), an area not extensively covered in existing literature. A cohort of patients with CAD was recruited from the Medical Information Mart for Intensive Care-IV database, and categorized into quartiles based on their TyG index. The primary outcome was AKI incidence, and the secondary outcome was renal replacement therapy (RRT). Scatterplot histograms, cox proportional hazards models, Kaplan-Meier survival curves, and restricted cubic splines were employed to investigate the association between the TyG index and the risk of AKI in patients with CAD. A total of 1,501 patients were enrolled in this study, predominantly male (61.56%), with a median age of 69.80 years. The AKI incidence was 67.22% among all patients, with the AKI stages increased with higher TyG levels (P for trend p < 0.001). Additionally, the restricted cubic spline analysis revealed a non-linear association between the TyG index and the risk of AKI (P for non-linear =0.637). Both multivariate Cox proportional hazards analyses (HR 1.62; 95% CI 1.15-2.27; p = 0.005) and multivariate logistic regression analyses (OR 2.16; 95% CI 1.18-3.94; p = 0.012) showed that the elevated TyG index was significantly related to AKI incidence. The association between TyG index and the risk of AKI is more significant in patients without diabetes (HR 1.27; 95% CI 1.14-1.42; p < 0.001), compared to patients with diabetes (P for interaction =0.013). In summary, the TyG index emerged as a reliable predictor for the occurrence of AKI in CAD patients during ICU stay. Furthermore, it is also anticipated to serve as a valuable indicator for non-diabetic patients in predicting the incidence of AKI.


  • Open Access

    Impact of preoperative anemia in ischemic cardiomyopathy with or without coronary artery bypass grafting

    by Yang Huang, Kaizheng Liu, Gang Li, Huawei Wu, Guangguo Fu, Bohao Jian, Jinyu Pan, Tongxin Chu, Yi Zhang, Mengya Liang, et al.

    Background: Whether the preoperative anemia affects the prognosis and the therapeutic choice between coronary artery bypass grafting (CABG) or medical therapy alone in patients with ischemic cardiomyopathy (ICM) remains unclear. We assess the influence of preoperative anemia on long-term outcomes in ICM patients treated with medical therapy alone with or without CABG. Methods: Patients with preoperative hemoglobin were included from the Surgical Treatment of Ischemic Heart Failure (STICH) trial. The primary outcome was long-term all-cause mortality. Results: A total of 1,209 patients were enrolled, with 320 (26.5%) patients with anemia, and 889 (73.5%) without anemia. The median follow-up time was 9.7 years. Compared with patients without anemia, patients with anemia had a higher risk of all-cause mortality [adjusted hazard ratio (aHR): 1.15; 95% confidence interval (CI): 0.98 to 1.36] and cardiovascular mortality (aHR: 1.26; 95% CI: 1.04 to 1.53). Among patients with anemia, CABG provided a significant survival benefit compared with medical therapy alone (all-cause mortality: aHR: 0.64; 95% CI: 0.48 to 0.85; cardiovascular mortality: aHR: 0.54; 95% CI: 0.39 to 0.76). Though with borderline statistical significance, CABG also provided additional survival benefit among patients without anemia (all-cause mortality: aHR: 0.87; 95% CI: 0.73 to 1.03; cardiovascular mortality: aHR: 0.83; 95% CI: 0.68 to 1.01). Sensitivity analyses based on as-treated principle showed the consistent results. Conclusions: Preoperative anemia is an independent risk factor for mortality in patients with ICM, whereas preoperative anemia does not affect the long-term survival benefits associated with CABG, which might help surgeons in making rational therapeutic decisions during clinical practice.

  • Open Access

    Fhl1, a new spatially specific protein, regulates vein graft neointimal hyperplasia

    by Chaoqun Wang, Jiantao Chen, Zicong Feng, Bohao Jian, Suiqing Huang, Kangni Feng, Haoliang Liu, Zhuoming Zhou, Ziyin Ye, Jing Lu, et al.

    Background: Vein grafts are commonly employed in revascularisation surgery for multivessel coronary artery disease, yet neointimal hyperplasia (NIH) remains a critical impediment to the long‐term patency of these grafts. Despite this, effective methods to precisely identify and target interventions for the neointima are still inadequate.Methods: In this study, Sprague–Dawley (SD) rats were used to establish an external jugular vein transplantation model, and the NIH pathophysiological process was tracked across 11 time points (0–35 days) using various histological stains. Spatial transcriptomics was performed on normal veins and 19‐day grafts to explore gene expression in neointimal regions. Immunohistochemical analysis identified neointima‐specific markers, while NIH progression was assessed in SD rats with four and a half LIM domains protein 1 (Fhl1) knockout and in human saphenous veins (HSV) with adenovirus‐mediated Fhl1 overexpression.Results: Typical neointimal formation commenced by day 11 postgrafting and peaked at day 19. Neointimal cells originated from newly generated α‐SMA(+) repair cells located outside the grafted vein, displaying a hybrid fibroblast‐smooth muscle cell phenotype. Spatial transcriptomics identified stable and sustained Fhl1 expression within the neointima throughout the entire NIH phase. Systemic knockout of Fhl1 in SD rats via the phosphoinositide 3‐kinase pathway exacerbated graft inflammation, heightened cell proliferation, and accelerated NIH. Conversely, FHL1 overexpression in cultured HSV suppressed NIH.Conclusion: These findings indicate that, following grafting into the arterial system, the newly formed repair cells external to the grafted vein play a pivotal role in NIH, with neointimal cells exhibiting stable and continuous Fhl1 expression. Fhl1 serves as a protective factor against NIH both in vivo and in HSV, likely due to its anti‐inflammatory and anti‐proliferative effects.Key points: This study firstly used spatial transcriptomics technique to analyse the neointima and generated a specific neointimal transcriptomic atlas. Fhl1 exhibits specific and stable expression in the spatial region of the neointima. It has thus far the highest enrichment of expression in the neointima in NIH phases, suggesting that it is a prominent molecular biomarker of neointima. We generated rats with a Fhl1 deletion and found that insufficient Fhl1 expression caused an increase in the severity of vascular inflammation and proliferation during neointimal hyperplasia. Adenovirus‐mediated FHL1 overexpression in human saphenous vein have beneficial effects in preventing neointimal hyperplasia. These highlight its potential as a therapeutic target for mitigating vein graft failure associated with cardiovascular procedures. Spatial transcriptomics profiles and morphological observations demonstrated that a newly generated cell population outside the grafted vein with hybrid phenotype between SMCs and fibroblasts contributes to neointimal formation.


  • Mitral Valve Repair Versus Replacement in Patients Undergoing Concomitant Aortic Valve Replacement

    by Yi Zhang, Guangguo Fu, Gang Li, Bohao Jian, Rui Wang, Yang Huang, Tongxin Chu, Zhongkai Wu, Zhuoming Zhou, Mengya Liang